212 related articles for article (PubMed ID: 10890028)
1. Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer.
Wigmore SJ; Barber MD; Ross JA; Tisdale MJ; Fearon KC
Nutr Cancer; 2000; 36(2):177-84. PubMed ID: 10890028
[TBL] [Abstract][Full Text] [Related]
2. The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer.
Barber MD; Ross JA; Voss AC; Tisdale MJ; Fearon KC
Br J Cancer; 1999 Sep; 81(1):80-6. PubMed ID: 10487616
[TBL] [Abstract][Full Text] [Related]
3. Metabolic response to feeding in weight-losing pancreatic cancer patients and its modulation by a fish-oil-enriched nutritional supplement.
Barber MD; McMillan DC; Preston T; Ross JA; Fearon KC
Clin Sci (Lond); 2000 Apr; 98(4):389-99. PubMed ID: 10731472
[TBL] [Abstract][Full Text] [Related]
4. Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia.
Fearon KC; Barber MD; Moses AG; Ahmedzai SH; Taylor GS; Tisdale MJ; Murray GD
J Clin Oncol; 2006 Jul; 24(21):3401-7. PubMed ID: 16849754
[TBL] [Abstract][Full Text] [Related]
5. Modulation of the liver export protein synthetic response to feeding by an n-3 fatty-acid-enriched nutritional supplement is associated with anabolism in cachectic cancer patients.
Barber MD; Preston T; McMillan DC; Slater C; Ross JA; Fearon KC
Clin Sci (Lond); 2004 Apr; 106(4):359-64. PubMed ID: 14624668
[TBL] [Abstract][Full Text] [Related]
6. Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer.
Cerchietti LC; Navigante AH; Castro MA
Nutr Cancer; 2007; 59(1):14-20. PubMed ID: 17927497
[TBL] [Abstract][Full Text] [Related]
7. Effect of a fish oil-enriched nutritional supplement on metabolic mediators in patients with pancreatic cancer cachexia.
Barber MD; Fearon KC; Tisdale MJ; McMillan DC; Ross JA
Nutr Cancer; 2001; 40(2):118-24. PubMed ID: 11962246
[TBL] [Abstract][Full Text] [Related]
8. Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.).
Gebbia V; Majello E; Testa A; Pezzella G; Giuseppe S; Giotta F; Riccardi F; Fortunato S; Colucci G; Gebbia N
Cancer; 1996 Sep; 78(6):1300-7. PubMed ID: 8826954
[TBL] [Abstract][Full Text] [Related]
9. Enteral nutrition enriched with eicosapentaenoic acid (EPA) preserves lean body mass following esophageal cancer surgery: results of a double-blinded randomized controlled trial.
Ryan AM; Reynolds JV; Healy L; Byrne M; Moore J; Brannelly N; McHugh A; McCormack D; Flood P
Ann Surg; 2009 Mar; 249(3):355-63. PubMed ID: 19247018
[TBL] [Abstract][Full Text] [Related]
10. The use of a protein and energy dense eicosapentaenoic acid containing supplement for malignancy-related weight loss in children.
Bayram I; Erbey F; Celik N; Nelson JL; Tanyeli A
Pediatr Blood Cancer; 2009 May; 52(5):571-4. PubMed ID: 19090549
[TBL] [Abstract][Full Text] [Related]
11. Oral fish oil supplementation raises blood omega-3 levels and lowers C-reactive protein in haemodialysis patients--a pilot study.
Saifullah A; Watkins BA; Saha C; Li Y; Moe SM; Friedman AN
Nephrol Dial Transplant; 2007 Dec; 22(12):3561-7. PubMed ID: 17623719
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of high-dose fish oil capsules for patients with cancer-related cachexia.
Burns CP; Halabi S; Clamon G; Kaplan E; Hohl RJ; Atkins JN; Schwartz MA; Wagner BA; Paskett E
Cancer; 2004 Jul; 101(2):370-8. PubMed ID: 15241836
[TBL] [Abstract][Full Text] [Related]
13. Changes in nutritional, functional, and inflammatory markers in advanced pancreatic cancer.
Barber MD; Ross JA; Fearon KC
Nutr Cancer; 1999; 35(2):106-10. PubMed ID: 10693162
[TBL] [Abstract][Full Text] [Related]
14. The 'cancer cachectic factor'.
Tisdale MJ
Support Care Cancer; 2003 Feb; 11(2):73-8. PubMed ID: 12560934
[TBL] [Abstract][Full Text] [Related]
15. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort.
Jatoi A; Rowland K; Loprinzi CL; Sloan JA; Dakhil SR; MacDonald N; Gagnon B; Novotny PJ; Mailliard JA; Bushey TI; Nair S; Christensen B;
J Clin Oncol; 2004 Jun; 22(12):2469-76. PubMed ID: 15197210
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal study of weight, appetite, performance status, and inflammation in advanced gastrointestinal cancer.
O'Gorman P; McMillan DC; McArdle CS
Nutr Cancer; 1999; 35(2):127-9. PubMed ID: 10693165
[TBL] [Abstract][Full Text] [Related]
17. Anticachectic and antitumor effect of eicosapentaenoic acid and its effect on protein turnover.
Beck SA; Smith KL; Tisdale MJ
Cancer Res; 1991 Nov; 51(22):6089-93. PubMed ID: 1657378
[TBL] [Abstract][Full Text] [Related]
18. NTP technical report on the toxicity studies of Dibutyl Phthalate (CAS No. 84-74-2) Administered in Feed to F344/N Rats and B6C3F1 Mice.
Marsman D
Toxic Rep Ser; 1995 Apr; 30():1-G5. PubMed ID: 12209194
[TBL] [Abstract][Full Text] [Related]
19. Effects of an oral nutritional supplement containing eicosapentaenoic acid on nutritional and clinical outcomes in patients with advanced non-small cell lung cancer: randomised trial.
Sánchez-Lara K; Turcott JG; Juárez-Hernández E; Nuñez-Valencia C; Villanueva G; Guevara P; De la Torre-Vallejo M; Mohar A; Arrieta O
Clin Nutr; 2014 Dec; 33(6):1017-23. PubMed ID: 24746976
[TBL] [Abstract][Full Text] [Related]
20. Effect of omega-3 fatty acid supplementation on the arachidonic acid:eicosapentaenoic acid ratio.
Burns T; Maciejewski SR; Hamilton WR; Zheng M; Mooss AN; Hilleman DE
Pharmacotherapy; 2007 May; 27(5):633-8. PubMed ID: 17461697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
